93 research outputs found
Experimental Investigations on Dopamine Transmission Can Provide Clues on the Mechanism of the Therapeutic Effect of Amphetamine and Methylphenidate in ADHD
The aim of this review is to compare the
experimental evidence obtained from in vitro
studies on the effect of amphetamine and
methylphenidate on dopamine transmission with
the results obtained in animal models of
attention deficit hyperactivity disorder (ADHD).
This comparison can extend the knowledge on
the mechanism of action of the drugs used in
the therapy of ADHD and provide insight into
the etiology of ADHD. In particular, we
considered the results obtained from in vitro
methods, such as synaptosomes, cells in culture,
and slices and from in vivo animal models of
ADHD, such as spontaneous hypertensive rats
(SHR) and the Naples high-excitability (NHE)
rat lines. The different experimental approaches
produce consonant results and suggest that in
SHR rats, in contrast to Wistar Kyoto rats
(WKY), amphetamine and depolarization by
high K+ might release different pools of
dopamine-containing vesicles. The pool depleted
by amphetamine might represent dopamine
that is stored in large dense core vesicles,
whereas dopamine released by high K+ might
be contained in small synaptic vesicles (SSV).
The sustained dopamine transmission observed
in the nucleus accumbens of SHR but not WKY
rats can be supported by an elevated synthesis
and release, which also might explain the
stronger effect of methylphenidate on dopamine
release in SHR but not in WKY rats. This
hypothesis might enlighten the common
therapeutic effect of these drugs, although their
action takes place at different levels in
catecholaminergic transmission
Role of Prefrontal Cortex Dopamine and Noradrenaline Circuitry in Addiction
Understanding the mechanisms of drug dependence has been the goal of a large number of
neuroscientists, pharmacologists and clinicians who carried out research with the hope of
individuating and proposing an efficacious therapy for this disorder (Sofuoglu, 2010;
Kalivas and Volkow, 2011). Unfortunately, although huge efforts, drug dependence is still a
relevant health, social and economical problem (Popova et al., 2012; Hiscock et al., 2011;
Shorter and Kosten, 2011). Treatments for drug abuse are for the most part ineffective
because the molecular and cellular mechanisms through which drugs of abuse alter
neuronal circuitry are still unexplained and above all, because drugs of abuse determine a
global alteration of cerebral functions that govern behaviour through decision formation,
making therefore unfocused the identification of a pharmacological target (Volkow et al.,
2011; Schultz 2011). One of the first strategies pursued in drug dependence therapy was
directed to removal of pleasure associated with drug taking, but the compliance with the
treatment has been always limited, although it could improve when it was supported by
psychology based motivational therapy as in alcohol dependence (Krampe and Ehrenreich,
2010; Simkin and Grenoble, 2010). On the other hand it is not infrequent that heavy smokers
or heavy drinkers stop suddenly dependence just because their will overcome year-long
habits. Decision making is a process based on the interaction between prefrontal cortex
(PFC) and subcortical regions involved in reward and motivation, therefore it is likely that
failure in self-regulatory behavior, that is common in addicted subjects, could be dependent
upon the alteration of interactions between the prefrontal cortex and subcortical regions
(Heatherton and Wagner, 2011). In this chapter we will review the role of PFC in addiction
with particular attention to dopamine and norepinephrine transmission
Recommended from our members
Metabolomics Fingerprint Induced by the Intranigral Inoculation of Exogenous Human Alpha-Synuclein Oligomers in a Rat Model of Parkinson's Disease.
Parkinson's disease (PD) is considered a synucleinopathy because of the intraneuronal accumulation of aggregated α-synuclein (αSyn). Recent evidence points to soluble αSyn-oligomers (αSynO) as the main cytotoxic species responsible for cell death. Given the pivotal role of αSyn in PD, αSyn-based models are crucial for the investigation of toxic mechanisms and the identification of new therapeutic targets in PD. By using a metabolomics approach, we evaluated the metabolic profile of brain and serum samples of rats infused unilaterally with preformed human αSynOs (HαSynOs), or vehicle, into the substantia nigra pars compacta (SNpc). Three months postinfusion, the striatum was dissected for striatal dopamine (DA) measurements via High Pressure Liquid Chromatography (HPLC) analysis and mesencephalon and serum samples were collected for the evaluation of metabolite content via gas chromatography mass spectrometry analysis. Multivariate, univariate and correlation statistics were applied. A 40% decrease of DA content was measured in the HαSynO-infused striatum as compared to the contralateral and the vehicle-infused striata. Decreased levels of dehydroascorbic acid, myo-inositol, and glycine, and increased levels of threonine, were found in the mesencephalon, while increased contents of fructose and mannose, and a decrease in glycine and urea, were found in the serum of HαSynO-infused rats. The significant correlation between DA and metabolite content indicated that metabolic variations reflected the nigrostriatal degeneration. Collectively, the metabolomic fingerprint of HαSynO-infused rats points to an increase of oxidative stress markers, in line with PD neuropathology, and provides hints for potential biomarkers of PD
Prepuberal stimulation of 5-HT7-R by LP-211 in a rat model of hyper-activity and attention-deficit: permanent effects on attention, brain amino acids and synaptic markers in the fronto-striatal interface
The cross-talk at the prefronto-striatal interface involves excitatory amino acids, different receptors, transducers and modulators. We investigated long-term effects of a prepuberal, subchronic 5-HT7-R agonist (LP-211) on adult behaviour, amino acids and synaptic markers in a model for Attention-Deficit/Hyperactivity Disorder (ADHD). Naples High Excitability rats (NHE) and their Random Bred controls (NRB) were daily treated with LP-211 in the 5th and 6th postnatal week. One month after treatment, these rats were tested for indices of activity, non selective (NSA), selective spatial attention (SSA) and emotionality. The quantity of L-Glutamate (L-Glu), L-Aspartate (L-Asp) and L-Leucine (L-Leu), dopamine transporter (DAT), NMDAR1 subunit and CAMKIIα, were assessed in prefrontal cortex (PFC), dorsal (DS) and ventral striatum (VS), for their role in synaptic transmission, neural plasticity and information processing. Prepuberal LP-211 (at lower dose) reduced horizontal activity and (at higher dose) increased SSA, only for NHE but not in NRB rats. Prepuberal LP-211 increased, in NHE rats, L-Glu in the PFC and L-Asp in the VS (at 0.250 mg/kg dose), whereas (at 0.125 mg/kg dose) it decreased L-Glu and L-Asp in the DS. The L-Glu was decreased, at 0.125 mg/kg, only in the VS of NRB rats. The DAT levels were decreased with the 0.125 mg/kg dose (in the PFC), and increased with the 0.250 mg/kg dose (in the VS), significantly for NHE rats. The basal NMDAR1 level was higher in the PFC of NHE than NRB rats; LP-211 treatment (at 0.125 mg/kg dose) decreased NMDAR1 in the VS of NRB rats. This study represents a starting point about the impact of developmental 5-HT7-R activation on neuro-physiology of attentive processes, executive functions and their neural substrates
Recommended from our members
Modeling Parkinson's Disease Neuropathology and Symptoms by Intranigral Inoculation of Preformed Human α-Synuclein Oligomers.
The accumulation of aggregated α-synuclein (αSyn) is a hallmark of Parkinson's disease (PD). Current evidence indicates that small soluble αSyn oligomers (αSynOs) are the most toxic species among the forms of αSyn aggregates, and that size and topological structural properties are crucial factors for αSynOs-mediated toxicity, involving the interaction with either neurons or glial cells. We previously characterized a human αSynO (H-αSynO) with specific structural properties promoting toxicity against neuronal membranes. Here, we tested the neurotoxic potential of these H-αSynOs in vivo, in relation to the neuropathological and symptomatic features of PD. The H-αSynOs were unilaterally infused into the rat substantia nigra pars compacta (SNpc). Phosphorylated αSyn (p129-αSyn), reactive microglia, and cytokine levels were measured at progressive time points. Additionally, a phagocytosis assay in vitro was performed after microglia pre-exposure to αsynOs. Dopaminergic loss, motor, and cognitive performances were assessed. H-αSynOs triggered p129-αSyn deposition in SNpc neurons and microglia and spread to the striatum. Early and persistent neuroinflammatory responses were induced in the SNpc. In vitro, H-αSynOs inhibited the phagocytic function of microglia. H-αsynOs-infused rats displayed early mitochondrial loss and abnormalities in SNpc neurons, followed by a gradual nigrostriatal dopaminergic loss, associated with motor and cognitive impairment. The intracerebral inoculation of structurally characterized H-αSynOs provides a model of progressive PD neuropathology in rats, which will be helpful for testing neuroprotective therapies
THE INTERRELATIONSHIP OF DOPAMINE AND NORADRENALINE IN THE PREFRONTAL CORTEX : FROM PHYSIOOLGY TO THERAPY
Dopamine release and noradrenaline release in the prefrontal cortex are required for the control of neurobiological functions, whose alteration is considered to be critical in the aetiology of widespread diseases such as schizophrenia, depression and attention deficit hyperactivity disorder (ADHD). The therapeutic agents used in treating these diseases may either increase or reduce dopamine and noradrenaline transmission by acting at receptor or at reuptake site level. The capacity of noradrenaline terminals to capture dopamine by means of the noradrenaline transporter (NET) has opened up new perspectives on the mechanism of action of norepinephine reuptake blockers such as long-established antidepressants or the new therapeutic agent for ADHD, atomoxetine. On the other hand, the hypothesis that dopamine and noradrenaline may be co-released from noradrenaline terminals in the prefrontal cortex suggests an additional interpretation of experimental evidence on the regulation of both dopamine and noradrenaline release through the pre-synaptic 2 receptor. Moreover, the high affinity of noradrenaline for the dopamine D4 receptor and its role in the prefrontal cortex, as well as the capacity of atypical antipsychotics to increase both noradrenaline and dopamine release in this area of the brain, support the hypothesis that dopamine-noradrenaline interaction may have a crucial role in the aetiology and in the therapy of schizophrenia. This chapter will illustrate and discuss the evidence for and against the hypothesis that there is an interdependence between dopamine and noradrenaline transmission in the prefrontal cortex, taking into consideration some recent evidence from our laboratory on the effect of chronic treatment with methylphenidate and atomoxetine on dopamine and noradrenaline release in the prefrontal cortex.
Available Options:
Version: Download: Windows - Englis
Dopamine reuptake by norepinephrine neurons: exception or rule?
Crit Rev Neurobiol. 2004;16(1-2):121-8.
Dopamine reuptake by norepinephrine neurons: exception or rule?
Carboni E, Silvagni A.
Department of Toxicology and Centre of Excellence on Neurobiology of Addiction,
University of Cagliari, Cagliari, Italy. [email protected]
Dopamine reuptake by norepinephrine terminals can occur in brain areas such as
the prefrontal cortex, the nucleus accumbens shell, and the bed nucleus of stria
terminalis that are innervated, although unevenly, by both dopamine and
norepinephrine neurons. Therefore the antidepressants that bind selectively the
norepinephrine transporter might produce their therapeutic effect by raising the
extracellular concentration of dopamine besides that of norepinephrine. Moreover,
cocaine can be reinforcing even in knock-out mice for the dopamine transporter
because it might raise synaptic dopamine in the nucleus accumbens shell by
preventing its uptake by the norepinephrine transporter, an effect that could
take place even in wild animals. Recently, it has also been suggested that
dopamine can be co-released with norepinephrine by norepinephrine neurons,
although it is not clear whether this feature might be related to a previous
nonspecific uptake of dopamine by the norepinephrine transporter. In this review
we discuss the potential role of the nonspecific uptake of dopamine by
norepinephrine transporter in the mechanism of action of drugs of abuse,
antipsychotics, and antidepressants.
PMID: 15581407 [PubMed - indexed for MEDLINE
- …